Figure 1
From: Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells
Sensitivity of BCR/ABL1-expressing leukemic cells to homologous recombination repair defects (HRD) and PARPi. (a) Immunoblot showing expression of BRCA1 in hematopoietic cells from BCR/ABL1-transgenic mice and wild-type (WT) mice. (b) BCR/ABL1 suppresses HRR activity. HRR activity was assessed in mock- or BCR/ABL1-transduced MRC5SV cells harboring a single integrated copy of DR-GFP. GFP expression was measured by flow cytometry at 48 h post-transfection of I-SceI. The percentages of GFP-positive cells are shown in the bar graph. *p = 0.03. (c) (d) Percentage of apoptotic hematopoietic mononuclear cells derived from WT and BCR/ABL1 Tg mice. Cells were treated for 24 h with the indicated concentrations of olaparib (*p = 0.02 and **p = 0.01) (c), or with 5 μM of olaparib, for the indicated times (d) (*p = 0.02, **p = 0.01). The percentage of induced apoptotic cells was obtained by subtracting the percentage of untreated cells. The data in the bar graph represent the mean ± standard deviation (SD) of three independent experiments.
